126 related articles for article (PubMed ID: 24288291)
1. Secondary metabolites from Eupenicillium parvum and their in vitro binding affinity for human opioid and cannabinoid receptors.
León F; Gao J; Dale OR; Wu Y; Habib E; Husni AS; Hill RA; Cutler SJ
Planta Med; 2013 Dec; 79(18):1756-61. PubMed ID: 24288291
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolic derivatives from Eupenicillium parvum.
Habib E; León F; Bauer JD; Hill RA; Carvalho P; Cutler HG; Cutler SJ
J Nat Prod; 2008 Nov; 71(11):1915-8. PubMed ID: 18991460
[TBL] [Abstract][Full Text] [Related]
3. In vitro opioid receptor affinity and in vivo behavioral studies of Nelumbo nucifera flower.
Kumarihamy M; León F; Pettaway S; Wilson L; Lambert JA; Wang M; Hill C; McCurdy CR; ElSohly MA; Cutler SJ; Muhammad I
J Ethnopharmacol; 2015 Nov; 174():57-65. PubMed ID: 26260436
[TBL] [Abstract][Full Text] [Related]
4. In Vitro and In Silico Studies of Neolignans from
Pandey P; Kumarihamy M; Chaturvedi K; Ibrahim MAM; Lambert JA; Godfrey M; Doerksen RJ; Muhammad I
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770918
[No Abstract] [Full Text] [Related]
5. Mastering tricyclic ring systems for desirable functional cannabinoid activity.
Petrov RR; Knight L; Chen SR; Wager-Miller J; McDaniel SW; Diaz F; Barth F; Pan HL; Mackie K; Cavasotto CN; Diaz P
Eur J Med Chem; 2013 Nov; 69():881-907. PubMed ID: 24125850
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
[TBL] [Abstract][Full Text] [Related]
7. Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors.
Pasquini S; De Rosa M; Ligresti A; Mugnaini C; Brizzi A; Caradonna NP; Cascio MG; Bolognini D; Pertwee RG; Di Marzo V; Corelli F
Eur J Med Chem; 2012 Dec; 58():30-43. PubMed ID: 23085772
[TBL] [Abstract][Full Text] [Related]
8. Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity.
Khanolkar AD; Lu D; Ibrahim M; Duclos RI; Thakur GA; Malan TP; Porreca F; Veerappan V; Tian X; George C; Parrish DA; Papahatjis DP; Makriyannis A
J Med Chem; 2007 Dec; 50(26):6493-500. PubMed ID: 18038967
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid and Opioid Receptor Affinity and Modulation of Cancer-Related Signaling Pathways of Machaeriols and Machaeridiols from
Muhammad I; Ibrahim MA; Kumarihamy M; Lambert JA; Zhang J; Mohammad MH; Khan SI; Pasco DS; Balachandran P
Molecules; 2023 May; 28(10):. PubMed ID: 37241903
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.
Ashton JC; Wright JL; McPartland JM; Tyndall JD
Curr Med Chem; 2008; 15(14):1428-43. PubMed ID: 18537620
[TBL] [Abstract][Full Text] [Related]
11. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.
Rajasekaran M; Brents LK; Franks LN; Moran JH; Prather PL
Toxicol Appl Pharmacol; 2013 Jun; 269(2):100-8. PubMed ID: 23537664
[TBL] [Abstract][Full Text] [Related]
12. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
Haller VL; Cichewicz DL; Welch SP
Eur J Pharmacol; 2006 Sep; 546(1-3):60-8. PubMed ID: 16919265
[TBL] [Abstract][Full Text] [Related]
13. Tricyclic pyrazoles. Part 6. Benzofuro[3,2-c]pyrazole: a versatile architecture for CB2 selective ligands.
Pinna G; Loriga G; Lazzari P; Ruiu S; Falzoi M; Frau S; Pau A; Murineddu G; Asproni B; Pinna GA
Eur J Med Chem; 2014 Jul; 82():281-92. PubMed ID: 24922543
[TBL] [Abstract][Full Text] [Related]
14. Benzyl derivatives with in vitro binding affinity for human opioid and cannabinoid receptors from the fungus Eurotium repens.
Gao J; León F; Radwan MM; Dale OR; Husni AS; Manly SP; Lupien S; Wang X; Hill RA; Dugan FM; Cutler HG; Cutler SJ
J Nat Prod; 2011 Jul; 74(7):1636-9. PubMed ID: 21667972
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis.
Benito C; Romero JP; Tolón RM; Clemente D; Docagne F; Hillard CJ; Guaza C; Romero J
J Neurosci; 2007 Feb; 27(9):2396-402. PubMed ID: 17329437
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors.
Brizzi A; Brizzi V; Cascio MG; Bisogno T; Sirianni R; Di Marzo V
J Med Chem; 2005 Nov; 48(23):7343-50. PubMed ID: 16279794
[TBL] [Abstract][Full Text] [Related]
17. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner.
Zádor F; Lénárt N; Csibrány B; Sántha M; Molnár M; Tuka B; Samavati R; Klivényi P; Vécsei L; Marton A; Vizler C; Nagy GM; Borsodi A; Benyhe S; Páldy E
Neuropharmacology; 2015 Feb; 89():298-307. PubMed ID: 25446673
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the pharmacology of imidazolidinedione derivatives at cannabinoid CB1 and CB2 receptors.
Govaerts SJ; Muccioli GG; Hermans E; Lambert DM
Eur J Pharmacol; 2004 Jul; 495(1):43-53. PubMed ID: 15219819
[TBL] [Abstract][Full Text] [Related]
19. Conformationally constrained analogs of BAY 59-3074 as novel cannabinoid receptor ligands.
Teng H; Thakur GA; Makriyannis A
Bioorg Med Chem Lett; 2011 Oct; 21(19):5999-6002. PubMed ID: 21880487
[TBL] [Abstract][Full Text] [Related]
20. Tricyclic Pyrazole-Based Compounds as Useful Scaffolds for Cannabinoid CB
Asproni B; Murineddu G; Corona P; Pinna GA
Molecules; 2021 Apr; 26(8):. PubMed ID: 33917187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
